Secretory Leukocyte Protease Inhibitor in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma

Abstract

Objectives: Secretory leukocyte protease inhibitor (SLPI) is a protein found in body fluids and implicated as a prognostic factor in many cancers. There is limited research regarding serum and salivary SLPI in oral potentially malignant disorders (OPMDs) and oral squamous cell carcinoma (OSCC). Materials and Methods: A total of 90 participants were included in the study; of which 30 formed the control group, 30 included participants with OPMD, and 30 included participants with OSCC. Serum and salivary levels of SLPI were estimated using enzyme-linked immunosorbent assay. Results: Serum levels of SLPI showed progressive increase in potentially malignant disorders and SCC patients when compared with controls, while salivary levels were increased in both OPMD and OSCC groups as compared to controls. However, the difference between groups was not statistically significant (P < 0.05). Conclusion: The above results suggest that increase in SLPI levels in the serum may have a role in indicating progression of OPMD to OSCC.

Keywords

Oral potentially malignant disorders - oral squamous cell carcinoma - saliva - Secretory leukocyte protease inhibitor - serum

• References

• 1 Shah FD, Begum R, Vajaria BN, Patel KR, Patel JB, Shukla SN. et al. A review on salivary genomics and proteomics biomarkers in oral cancer. Indian J Clin Biochem 2011; 26: 326-34
• 2 Rivera C, Venegas B. Histological and molecular aspects of oral squamous cell carcinoma (Review). Oncol Lett 2014; 8: 7-11
• 3 Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun 2005; 73: 1271-4
• 4 Pushpanshu K, Sathawane RS, Kaushik R. Estimation and comparison of salivary secretory leukocyte protease inhibitor in human immunodeficiency virus patients and healthy individuals. Indian J Palliat Care 2014; 20: 26-30
• 5 Pierce Campbell CM, Giuliano AR, Torres BN, O’Keefe MT, Ingles DJ, Anderson RL. et al. Salivary secretory leukocyte protease inhibitor (SLPI) and head and neck cancer: The cancer prevention study II nutrition cohort. Oral Oncol 2016; 55: 1-5
• 6 Yang Y, Rhodus NL, Ondrey FG, Wuertz BR, Chen X, Zhu Y. et al. Quantitative proteomic analysis of oral brush biopsies identifies secretory leukocyte protease inhibitor as a promising, mechanism-based oral cancer biomarker. PLoS One 2014; 9: e95389
• 7 Lin AL, Johnson DA, Stephan KT, Yeh CK. Salivary secretory leukocyte protease inhibitor increases in HIV infection. J Oral Pathol Med 2004; 33: 410-6
• 8 Hoffmann M, Quabius ES, Tribius S, Hebebrand L, Görögh T, Halec G. et al. Human papillomavirus infection in head and neck cancer: The role of the secretory leukocyte protease inhibitor. Oncol Rep 2013; 29: 1962-8
• 9 Wang G, Lim DS, Choi BD, Park JJ, Jeong SJ, Kim JS. et al. Effect of secretory leukocyte protease inhibitor on migration and invasion of human KB oral carcinoma cells. Animal Cells Syst 2011; 15: 139-46
• 10 Liu G, Yang J, Zhao Y, Wang Z, Xing B, Wang L. et al. Expression of secretory leukocyte protease inhibitor detected by immunohistochemistry correlating with prognosis and metastasis in colorectal cancer. World J Surg Oncol 2014; 12: 369
• 11 Simpkins FA, Devoogdt NM, Rasool N, Tchabo NE, Alejandro EU, Kamrava MM. et al. The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells. Carcinogenesis 2008; 29: 466-72
• 12 Sayers KT, Brooks AD, Sayers TJ, Chertov O. Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells. PLoS One 2014; 9: e104223
• 13 Zhang W, Yao JL, Dong SC, Hou FQ, Shi HP. SLPI knockdown induced pancreatic ductal adenocarcinoma cells proliferation and invasion. Cancer Cell Int 2015; 15: 37
• 14 Cordes C, Häsler R, Werner C, Görögh T, Röcken C, Hebebrand L. et al. The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma. Int J Oncol 2011; 39: 185-91
• 15 Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H. et al. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci U S A 2003; 100: 5778-82
• 16 Quabius ES, Möller P, Haag J, Pfannenschmidt S, Hedderich J, Görögh T. et al. The role of the antileukoprotease SLPI in smoking-induced human papillomavirus-independent head and neck squamous cell carcinomas. Int J Cancer 2014; 134: 1323-34
• 17 Pierce Campbell CM, Guan W, Sprung R, Koomen JM, O’Keefe MT, Ingles DJ. et al. Quantification of secretory leukocyte protease inhibitor (SLPI) in oral gargle specimens collected using mouthwash. J Immunol Methods 2013; 400-401: 117-21
• 18 Salian V, Dinakar C, Shetty P, Ajila V. Etiological trends in oral squamous cell carcinoma: A retrospective institutional study. Cancer Transl Med 2016; 2: 33-6
• 19 Mathur PT, Dayal PK, Pai K. Correlation of clinical patterns of oral squamous cell carcinoma with age, site, sex and habits. J Indian Acad Oral Med Radiol 2011; 23: 81-5
• 20 Feller L, Lemmer J. Oral squamous cell carcinoma: Epidemiology, clinical presentation and treatment. J Cancer Ther 2012; 3: 263-8
• 21 Balakrishnan C, Aswath N. Estimation of serum, salivary immunoglobulin G, immunoglobulin A levels and total protein, hemoglobin in smokeless tobacco chewers and oral submucous fibrosis patients. Contemp Clin Dent 2015; 6: S157-62
• 22 Wen J, Nikitakis NG, Chaisuparat R, Greenwell-Wild T, Gliozzi M, Jin W. et al. Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma. Am J Pathol 2011; 178: 2866-78